In the 20 years since its discovery, research into the NF-κB (nuclear factor-κB) family of transcription factors has revealed an amazing diversity of functions. NF-κB proteins are regulators of the immune, inflammatory, stress, proliferative and apoptotic responses of a cell to a very large number of different stimuli. NF-κB complexes can be found in all cell types, indicating that the number of different contexts in which NF-κB can become induced is enormous. Moreover, many reports suggest apparently opposing or contradictory functions for NF-κB. It is clear that it is not simply enough to understand the pathways leading to nuclear localization and DNA binding of NF-κB subunits. It is also important that we comprehend the regulation of NF-κB subunit functionality if we are to understand the NF-κB pathway as a whole. These issues include the mechanisms controlling the specificity and timing of genes regulated by NF-κB under particular circumstances. They also include the reasons why NF-κB subunits can sometimes repress rather than activate transcription and how the NF-κB response is integrated with other important transcription factor pathways in the cell, such as the induction of the p53 tumour suppressor following DNA damage or oncogene activation. Understanding the mechanisms that regulate NF-κB function has important implications for our understanding of the role that NF-κB subunits play in human inflammatory diseases and cancer, and could also impact on the use of future NF-κB-based clinical therapies.
Introduction
NF-κB (nuclear factor-κB) was first reported as a nuclear protein necessary for Igκ light chain transcription in B cells [1] . It is now known that NF-κB exists in most cell types, held in the cytoplasm as an inactive form directly bound to a member of the IκB (inhibitor of NF-κB) protein family [2] . NF-κB complexes are composed of homo-or hetero-dimers from the multigene family of RelA/ 1 To whom correspondence should be addressed (email n.d.perkins@dundee.ac.uk).
Canonical and non-canonical activation of NF-κB
Two distinct pathways to NF-κB activation have emerged in recent years. The canonical pathway of NF-κB activation releases dimers composed of RelA, c-Rel and p50 from IκB sequestration [11] . Release from IκB sequestration in the cytoplasm allows translocation of NF-κB to the nucleus, where it can influence the transcription of a diverse set of target genes [12] . Upon stimulation with pro-inflammatory cytokines or microbial infection, the canonical pathway is activated through the IKK-mediated phosphorylation of NF-κB-bound IκBα at Ser 32 and Ser 36 (or equivalent residues in other IκB proteins) [11] . This results in polyubiquitination at Lys 21 and Lys 22 by a specific ubiquitin ligase of the SCF (Skp1/Cul1/F-box) family [11] . This triggers ubiquitin-dependent IκB degradation by the 26 S proteasome, leaving NF-κB dimers to translocate to the nucleus [11] . The IKK signalosome is a cytoplasmic complex of over 700 kDa, and is known to include kinase activity in the form of IKKα and IKKβ, and a non-kinase regulatory subunit, IKKγ [11] . Canonical activation depends on the IKKβ activity of the IKK complex. Although IKKγ has no intrinsic kinase activity, in vivo it is required for IKKα and IKKβ activity and is thought to function as a scaffold protein [11] .
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In addition to the canonical pathway, an alternative (non-canonical) pathway of NF-κB activation occurs in response to stimulation of the CD40 receptor and lymphotoxin-β receptor or by B-cell-activating factor and LMP-1 (latent membrane protein-1) of the Epstein-Barr virus [3, 13, 14] . The non-canonical pathway of NF-κB activation involves p100. Non-canonical inducing stimuli activate the NF-κB-inducing kinase, which in turn induces IKKα activity. IKKα then phosphorylates p100, inducing its polyubiquitination and proteolytic removal of the C-terminal, ankyrin-repeat-containing, domain, allowing p52-containing dimers to translocate to the nucleus [3, 13, 14] . This is different from signal-induced p105 processing, which requires IKKβ [3] . These distinct activation pathways therefore control the composition of nuclear NF-κB dimers.
Typical compared with atypical NF-κB activators
In addition to the canonical and non-canonical pathways, we believe that NF-κB function can be understood further by considering the inducers of NF-κB as belonging to either typical or atypical classes of activators. Among the better characterized inducers of NF-κB are inflammatory cytokines and bacterial products that culminate in activation of the IKK signalosome [11] . Upon stimulation by TNFα (tumour necrosis factor α), IL-1 (interleukin-1) or LPS (lipopolysaccharide), nuclear translocation of NF-κB is rapid and peaks by 1 h, which, by our criteria, classifies these as 'typical' activators of NF-κB. NF-κB is also activated by stimuli relevant to tumour initiation, promotion and therapy [12] . Such inducers include UV-C, ionizing radiation, phorbol esters, hypoxia and the chemotherapeutic agents daunorubicin, doxorubicin, etoposide, camptothecin, vincristine, vinblastine and cisplatin [12] . Activators such as UV-C and some chemotherapeutic compounds can be classified as 'atypical'. Here, induction of NF-κB DNA binding occurs with slower kinetics and through a pathway distinct from that utilized by inflammatory cytokines. For example, UV-C and doxorubicin have been shown to induce NF-κB DNA binding in an IKK-independent manner without phosphorylation of Ser 32 and Ser 36 of IκBα [15] [16] [17] [18] . However, other reports have indicated that IKK activity is required for these activators [19, 20] , but may be utilized in a novel way, with a requirement for the zinc finger domain of IKKγ, which is not found with typical inducers such as TNFα and LPS [21, 22] . In addition, other stimuli, such as hypoxic injury and oxidative stress, have been shown to activate NF-κB through induction of tyrosine phosphorylation of IκBα [23, 24] . The situation appears complex, but it is reasonable to say that NF-κB activation by atypical activators occurs with delayed kinetics and utilizes IKK in a manner distinct from typical inducers such as TNFα, IL-1 and LPS. 
NF-κB target genes
For simplicity, NF-κB target genes can be grouped into four subsets based on function. The first group is involved in the inflammatory response and immunoregulatory functions. This group is typified by pro-inflammatory cytokines, chemokines and their receptors, such as TNFα, IL-1, IL-6, MIP-1α (monocyte chemoattractant protein-1α) and RANTES (regulated upon activation, normal T-cell expressed and secreted), together with adhesion molecules such as VCAM-1 (vascular cell adhesion molecule-1), ICAM-1 (intercellular cell adhesion molecule-1) and ELAM-1 (endothelial-leucocyte adhesion molecule-1) [12] . Amplification of the NF-κB response therefore occurs, as binding of TNFα and IL-1 to their receptors strongly activates NF-κB [12] . Chronic inflammatory diseases such as rheumatoid arthritis can develop if this production of inflammatory cytokines goes unchecked [9] . Therefore the second subset of NF-κB target genes are negative regulators of NF-κB. Expression of these proteins provides a feedback mechanism to curtail the NF-κB response. This is exemplified by IκBα, the anti-apoptotic protein A20, and the tumour suppressor CYLD [12, 25] . The third subset are genes with an apoptotic function. These include anti-apoptotic gene products such as IAP (inhibitor of apoptosis) proteins, TRAFs (TNFα-receptor-associated factors) and Bcl-xL, as well as pro-apoptotic genes such as those encoding Fas and Fas Ligand (see below) [26] . The final subset of NF-κB target genes encode positive regulators of the cell cycle. For example, cyclin D1 and Myc promote cell growth, and their expression is regulated by NF-κB [27, 28] . NF-κB target genes from all four of these groups can contribute towards tumorigenesis [7] .
NF-κB activity is subject to regulation at multiple levels
Numerous mechanisms exist to ensure appropriate control of transcription factor activity. In particular, regulation of NF-κB activity occurs at multiple levels to generate exquisite control of transcriptional activity ( Figure 1 ) [29] . NF-κB activity is firstly regulated at the level of IκB proteins. Upon stimulation by TNFα or IL-1, activated NF-κB induces IκBα expression. This IκBα moves to the nucleus, where it binds to RelA and p50, preventing DNA binding, before shuttling back to the cytoplasm [30] . This rapidly turns off the NF-κB response and can result in an oscillatory activation profile. Computational models have revealed that IκBβ and IκBε, whose expression is not regulated by NF-κB, stabilize the NF-κB response during sustained stimulation, dampening the oscillatory potential [31] . This bimodal NF-κB response manifests physiologically as an ability to generate substantial responses to short stimulations while also responding to stable long-term stimulation. Hoffmann and colleagues [31] further identified two classes of TNFα-inducible NF-κB target genes, illustrated by the chemokines IP-10 (interferon γ inducible protein 10; activated by short stimulation with TNFα) and RANTES (requires sustained NF-κB activation for expression). Thus IκBα, IκBβ and IκBε can control the intensity, duration and (to a certain extent) specificity of the NF-κB response.
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Specific kinase cascades have been implicated upstream of IKK and these can determine the nature of the NF-κB response. MEKK3 (mitogen-activated protein kinase kinase kinase 3) is essential for the rapid activation of NF-κB by TNFα and the formation of an IκBα-NF-κB-IKK complex [32, 33] . Using alternative kinase pathways upstream of IKK, the cell can regulate the kinetics of NF-κB activation. This is illustrated by the activation of MEKK2, which unlike MEKK3 was found to be necessary for the second phase of TNFα-or IL-1α-induced NF-κB activity and the assembly of an IκBβ-NF-κB-IKK complex [32] . Although TNFα-induced NF-κB DNA binding in MEKK3 null cells is impaired, UV-induced DNA binding is unaffected [33] . Therefore different kinase pathways upstream of IKK could explain why atypical activators trigger NF-κB DNA binding with much slower kinetics than typical activators. Several NF-κB dimer combinations are possible, and the composition of the NF-κB complex can change with time following cell stimulation [34] . Since different NF-κB subunits have distinct DNA sequence affinities and transactivation properties, this diversity adds another level of specificity to the NF-κB pathway. However, as NF-κB sites in target genes are frequently bound by multiple NF-κB dimer combinations, differences in DNA-binding specificity cannot account completely for most differential regulation of NF-κB target genes [6, 34] . Transcriptional regulation by NF-κB can be achieved through differential interactions with co-activator and co-repressor proteins. Association with co-activators such as p300/CBP [CREB (cAMP response element-binding protein) binding protein], P/CAF (p300/CBP-associated factor) and the steroid receptor co-activator Src1 enhance activation of NF-κB through recruitment of histone acetylase activity [35] [36] [37] . Similarly, association with HDACs (histone deacetylases) can repress NF-κB through hypoacetylation of promoters where RelA is bound [38] [39] [40] [41] . Promoter-bound NF-κB can also be influenced by the presence of heterologous transcription factors. Examples of this include an interaction between Sp1 and NF-κB, which induces HIV-1 gene transcription [42] . Similarly, IRFs (interferon response factors) and ATF2 (activating transcription factor 2)/c-Jun co-operate with NF-κB to induce expression of interferon-β [43] . The recent discovery that κB site sequence can determine both the DNA-binding affinity of NF-κB complexes as well as the ability of bound NF-κB dimers to interact productively with cofactors provides a new dimension to promoter-specific NF-κB activity [44] . Therefore NF-κB activity at specific promoters may be determined by the presence or absence of other transcription factors and cofactors.
Post-translational modification of the NF-κB subunits provides another level at which NF-κB activity can be regulated, and has emerged as a dynamic mechanism controlling RelA transactivation, DNA-binding capabilities and stability. These modifications have recently been reviewed elsewhere [45, 46] , and for the RelA subunit alone include phosphorylation, dephosphorylation, acetylation, deacetylation, ubiquitination and prolyl isomerization. In particular, phosphorylation of the RelA transactivation domain appears to determine whether RelA activates or represses transcription [47] (and see below), while phosphorylation within the RHD can determine targeting to different promoters [48] . Much remains to be discovered about the importance of post-translational modifications of NF-κB, however. In particular, virtually nothing is known about how such events regulate the function of subunits other than RelA.
A final level of control of NF-κB activity is exercised by the chromatin environment of target genes. This was first illustrated by LPS stimulation of macrophages, which results in biphasic recruitment of NF-κB to target gene promoters, determined by histone acetylation [49] . At constitutively acetylated promoters, NF-κB DNA binding is rapid, whereas hypoacetylated promoters require additional events leading to their hyperacetylation prior to NF-κB recruitment and activation of transcription. This demonstrates the important point that total NF-κB DNA binding, as determined by electrophoretic mobility shift assay, is not adequate evidence of activity at individual promoters. Histone phosphorylation can also mark some promoters for RelA recruitment © 2006 The Biochemical Society [50] . This could be a reciprocal relationship, as RelA-associated IKKα was recently identified as a putative histone kinase [51, 52] . Therefore the chromatin environment of NF-κB target genes may contribute to the specificity of the NF-κB response. Together, these levels of control must account for the ability of NF-κB to respond to over 150 distinct activators [12] , with defined patterns of gene expression triggering diverse cellular outcomes [12] . Delineating the determinants of NF-κB functionality should lead to a better understanding of the role of NF-κB in disease.
RelA and apoptosis
A large number of reports describe NF-κB-dependent regulation of apoptosis [26] . The majority of these reports describe NF-κB, and the RelA subunit in particular, as being an anti-apoptotic transcription factor. This view first arose from early work describing the phenotype of rela null mice. These mice die during embryogenesis as a result of massive liver apoptosis arising from increased sensitivity to TNFα [53] . This embryonic lethality was completely suppressed in the absence of TNFα or TNFα receptor 1 [54, 55] . Consistent with this hypothesis, NF-κB has been shown to be required for suppression of TNFα-, etoposide-and daunorubicin-induced apoptosis [26] . Mechanistically, this can be explained by the fact that NF-κB regulates anti-apoptotic genes, such as those encoding A20, IAP1, IAP2, TRAF1, TRAF2, Bfl-1/A1 and Bcl-xL [26] . However, NF-κB target genes also include those encoding pro-apoptotic proteins, such as Fas, FasL, DR4 (death receptor 4) and DR5 [26] . Therefore, whether NF-κB prevents or facilitates apoptosis is stimulus-, cell type-and context-dependent. Table 1 highlights examples of cases where NF-κB, and specifically the RelA subunit, has been reported to be anti-apoptotic in contexts relevant to tumour initiation, development or therapy. The majority of reports of NF-κB function in these contexts suggest an anti-apoptotic function for RelA. Other studies concluded that there is no role for NF-κB in the regulation of chemotherapy-induced apoptosis. For example, Bentires-Alj and co-workers [56] studied the effects of stable expression of IκBαSR (super-repressor IκB) in lymphoid T cells, and colorectal adenocarcinoma, breast cancer and ovarian carcinoma cells. Surprisingly, they found that survival following treatment with TNFα, mitomycin C, camptothecin, daunorubicin, taxol or vinblastine was not significantly different between parental cells and those expressing IκBαSR. Another study utilized IκBαSR in breast and colon carcinoma cells, but identified no role for NF-κB in the control of daunorubicin-induced apoptosis or cell cycle progression [57] . On the other hand, additional reports revealed both pro-and anti-apoptotic functions of NF-κB in HeLa cells, dependent on stimulation with TNFα (anti-apoptotic), hydrogen peroxide and pervanadate (pro-apoptotic) [58] . This was echoed in a more recent study where it was shown that, in response to camptothecin, NF-κB inhibition protected against p53-mediated neuronal cell death [59] . However, a dual role for RelA in these cells was revealed, Table 2 . It is possible that the situation has been confused by some of the methodology used to determine dependence on NF-κB. For example, relatively non-specific compounds such as proteasome inhibitors are frequently used to infer NF-κB-specific effects without formally showing NF-κB dependence (Tables 1 and 2 ). Similarly, a dominant negative IκB super-repressor (IκBSR) is commonly utilized to reveal NF-κB-dependent effects (Tables 1 and 2 ). IκBSR is unable to be phosphorylated and degraded by classical activation pathways, as it has an N-terminal truncation, or point mutations removing Ser 32 and Ser 36 phosphorylation sites or Lys 22 and Lys 23 ubiquitination sites [11] . However, IκBSR can affect non-NF-κB pathways. Overexpression of IκBSR may affect nuclear import/export pathways [60] , and overexpressed IκBα can interact with other proteins, such as CDK4 (cyclin-dependent kinase 4) [61] and p53 [62, 63] . Indeed, IκBSR has been reported to prevent p53-dependent apoptosis through interaction with p53 [63] . Therefore, uncertainty still exists about the actual function of RelA and NF-κB in these contexts.
We have recently investigated the role of RelA as a regulator of apoptosis following stimulation with atypical inducers of NF-κB. We had noticed that, in many reports where atypical activators induced NF-κB that primed cells for apoptosis, little was reported of the transcriptional targets and activity of NF-κB. Furthermore, many studies of atypical inducers rely on NF-κB DNA binding as an indicator of transcriptional activity. Surprisingly, we found that following cell stimulation with UV light or the chemotherapeutic drugs daunorubicin or doxorubicin (adriamycin), RelA repressed rather than induced the expression of anti-apoptotic genes such as those encoding Bcl-xL and XIAP [39] . We have observed similar results with the ARF tumour suppressor�� although ARF tumour suppressor�� although ARF does not induce NF-κB DNA binding, it modulates existing NF-κB activity, converting RelA into a repressor of Bcl-xL expression, thus sensitizing cells to apoptotic stimuli [47, 64] . In both cases transcriptional repression by RelA is associated with its differential phosphorylation and increased association with HDACs, although UV and daunorubicin/doxorubicin appear to work through distinct signalling pathways to ARF [39, 47] . While these results are probably not the whole story concerning the pro-apoptotic effects of RelA and NF-κB, they do illustrate an important point, namely that NF-κB functionality can be determined by post-translational modification of the NF-κB subunits.
NF-κB has both oncogenic and tumour suppressor properties
Considerable evidence suggests a link between NF-κB and cancer. However, this relationship is not straightforward. The RelA subunit of NF-κB in particular can display both oncogene-and tumour suppressor-like capabilities. The functional differences described above, particularly differential regulation of apoptosis, will probably contribute to the nature of NF-κB regulation of tumorigenesis. NF-κB is required for the transforming properties of oncogenes such as activated Ras and Bcr-Abl [65] . Viral oncoproteins have also been shown to utilize NF-κB for transformation [66] . Examples of this are the TAX oncoprotein of HTLV-1 (human T-cell leukaemia virus-1), which interacts directly with IKKγ to cause constitutive activation of IKK, and hence NF-κB. Similarly, the Epstein-Barr virus protein LMP-1 increases NF-κB DNA binding and transcriptional activity. Furthermore, activation of NF-κB and IKK was recently found to make a significant contribution to inflammation-associated tumorigenesis in intestinal and liver tumours [67] . Interestingly, these studies also revealed a different role for NF-κB in different cell types. For example, in an ulcerative colitis model for colon cancer, regulation of apoptosis by IKK/NF-κB was found to be a critical at early stages in the development of enterocytes into viable tumours [68] . A critical role for NF-κB/IKK in non-transformed myeloid cells was also identified, but here the production of cytokines and chemokines stimulated cancer cell proliferation and growth at later stages of tumour growth [68] . Therefore, although NF-κB and IKK contribute to tumour development in both cell types, this occurs through at least two distinct mechanisms, presumably reflecting cell type-specific differences in gene regulation.
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There are also numerous examples where failure to negatively regulate NF-κB results in cancer. Constitutive NF-κB activity, through altered activity of upstream proteins, has been identified in haematopoietic and solid tumours [65] . For example, analysis of Hodgkin's disease cell lines and patient biopsies revealed mutated IκBα that was incapable of interacting with NF-κB [69] . Similarly, the CYLD tumour suppressor functions as a negative regulator of NF-κB signalling, through de-ubiquitination of IKKγ, TRAF2 and TRAF6 [70] . Therefore NF-κB activity can contribute towards tumorigenesis in many contexts.
Considerable evidence also exists that RelA is required to prevent tumorigenesis. A tumour-suppressing role for RelA first emerged from studies showing that, upon serum starvation, RelA was actually required for apoptosis [71] . This was corroborated by studies showing that expression of RelA could drive pro-B cells and breast cancer cells to apoptosis [72, 73] . These studies were taken into an in vivo setting when Khavari and colleagues showed that overexpression of RelA or p50 NF-κB subunits in the basal layer of mouse epidermis led to epidermal hypoplasia [74] . In the same setting, expression of IκBαSR caused hyperplasia [74] . Khavari and colleagues also found that human sporadic small-cell carcinoma may involve nuclear exclusion of the RelA subunit [75] . Indeed, co-expression of the IκBαSR and activated Ras resulted in neoplasia that resembled invasive small-cell carcinoma in human keratinocytes transplanted on to mice. van Hogerlinden and co-workers [76] also observed spontaneous development of squamous cell carcinomas in murine skin targeted with overexpressed IκBα, revealing that IκBα can be oncogenic. The hyperplasia observed by Khavari and colleagues has subsequently been attributed to enhanced JNK (c-Jun N-terminal kinase) activation induced by ikkβ or rela gene deficiency in the epidermis, resulting in a failure to activate apoptosis and an increase in cell proliferation [77] .
RelA has been reported to be required for p53-mediated cell death [78] . Furthermore, while the phenotype of rela null mice suggested an anti-apoptotic role for RelA, Gapuzan and co-workers [79] demonstrated that at least some derivatives of immortalized rela null mouse fibroblasts displayed a weakly transformed phenotype. These cells also formed tumours in nude mice which then regressed, indicating a requirement for additional mutations. These effects were reversed by re-expression of RelA, providing strong genetic evidence for a tumour suppressor role for RelA [79] . Furthermore, in vivo tumour models revealed that loss of RelA enhanced Ras-and E1A-induced tumorigenesis [80] . In agreement with these studies, it has emerged that, in colon-and breast-cancer cells, NF-κB target gene expression is repressed by β-catenin, found to be elevated in these tumours and in a complex with RelA and p50 [81] . Similarly, HSCO (hepatoma substracted cDNA library clone one) protein, found to be overexpressed in hepatocellular carcinomas, binds the RHD of RelA, sequestering it in the cytoplasm; it also prevents doxorubicin-and etoposide-induced, but not TNFα-induced, apoptosis [82] . Therefore considerable evidence has also revealed a tumour suppressor role for RelA.
Consistent with these studies, results from our laboratory and others have revealed mechanisms through which tumour suppressors can regulate the function of RelA and other NF-κB subunits and neutralize their oncogenic capabilities. In particular, our laboratory recently characterized regulation of RelA by the ARF tumour suppressor [47, 64] . ARF expression is induced upon aberrant oncogene activation, whereupon it inactivates Hdm2/Mdm2 (human/ murine double minute 2), the inhibitor of p53. Since one of the functions of p53 is to induce the expression of pro-apoptotic genes, the anti-apoptotic functions of RelA would reduce the effectiveness of the p53 response if left unchecked. We found that ARF activates the ATR (ataxia telangiectasia-related)/Chk1 (checkpoint kinase 1) kinases, in a manner functionally distinct from that seen upon DNA damage. Chk1 then phosphorylates Thr 505 of RelA, a residue within its transactivation domain. This phosphorylation event converts RelA into a repressor of Bcl-xL expression, thus sensitizing cells to apoptotic stimuli [47, 64] . At the early stages in the development of potential tumour cells, this mechanism will help to prevent the oncogenic function of RelA and can be thought of as recruiting RelA to the ARF tumour suppressor programme. If this mechanism is lost during tumour cell development, then the anti-apoptotic RelA activity of RelA is no longer suppressed and can contribute to tumour cell growth and survival [7] .
There are many other reports of tumour suppressors regulating NF-κB function. For example, multiple levels of cross-talk exist between p53 and NF-κB, with both antagonistic and co-operative functions being described [7] . Interestingly, we demonstrated that p53 can also regulate the activity of the p52 NF-κB subunit [83] . p52 NF-κB is a regulator of the cyclin D1 promoter [84] . Upon p53 expression, we observed loss of p52-Bcl-3 activator complexes and an increase in p52-HDAC1 complexes, resulting in repression of cyclin D1 expression [83] . Similar to regulation of RelA by ARF, this provides an example where NF-κB subunit activity is not merely inhibited by a pathway, but subverted and recruited to the tumour suppressor programme. Further evidence for this emerg-© 2006 The Biochemical Society ing theme of tumour suppressor modulation of NF-κB arises from the finding that the putative tumour suppressor protein ING4 (inhibitor of growth 4) interacts with RelA and represses transcription of NF-κB target genes, to inhibit brain tumour growth and angiogenesis [85] . Moreover, the PTEN (phosphatase and tensin homologue deleted on chromosome 10) tumour suppressor protein (the natural antagonist for phosphoinostide 3-kinase) also inhibits NF-κB transcriptional activity through inhibition of the RelA transactivation domain [86] . In addition, the p16 INK4a CDK4/6 inhibitor, which shares a genetic locus with ARF, has also been reported to interact physically with RelA, and p16 overexpression inhibits RelA transactivation [87] . Indeed, a study of primary melanomas and metastases revealed an inverse correlation between p16 expression and RelA nuclear localization [88] . It is conceivable that, similar to ARF, these other pathways do not merely inhibit RelA activity, but induce RelA's ability to repress transcription, thus converting RelA to its tumour suppressor form.
The devil is in the details
The complexity of the NF-κB response demands precise regulatory mechanisms to ensure that the specificity and selectivity of this pathway is utilized appropriately by the cell. Although many of these mechanisms often appear as relatively minor components of the NF-κB response, when compared with the more obvious regulatory events such as IκB degradation and NF-κB nuclear translocation, they are nonetheless critical in determining NF-κB function. Since NF-κB subunit functionality is ultimately key to determining the role that NF-κB plays in normal processes and disease, these regulatory mechanisms should not be ignored or sidelined. This could be particularly true when implementing NF-κB-based therapies, such as IKK inhibitors, or more general treatments, such as chemotherapeutic drugs that are known to activate or modulate NF-κB. The effectiveness of such treatments could well be determined by the NF-κB functional status in the target tissue or cell type. Furthermore, potential side effects might be influenced by the beneficial effects of NF-κB elsewhere. This is not an argument for refraining from the pursuit of NF-κB-based therapies, which have the potential to treat a wide range of diseases. Instead, understanding the mechanisms that regulate NF-κB functionality will lead to more effective use of existing and future therapies.
